Trials / Unknown
UnknownNCT02809534
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
A Single Group, Open Label, Single-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Hepatocellular Carcinoma (ALTER0802)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-06-22
- Last updated
- 2016-09-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02809534. Inclusion in this directory is not an endorsement.